LPS-induced biomarkers in mice: A potential model for identifying insulin sensitizers

Biochemical and Biophysical Research Communications

Volumn 361, Issue 1, 2007, Pages 140-145

  Briscoe, Celia P ^a   Looper, David ^a   Tran, Phong ^a   Herrera, Jocelyn ^a   McDonnell, Scott R ^a   Bhat, B Ganesh ^a  

^a PFIZER INC   (United States)

Author keywords

Biomarker; Insulin sensitizer; JNK; Lipopolysaccharide; Osteopontin; S6K

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INSULIN SENSITIZING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PROTEIN C JUN; PROTEIN S6; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; INFLAMMATION; INSULIN RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CYTOKINES; DISEASE MODELS, ANIMAL; INSULIN; INSULIN RESISTANCE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; OSTEOPONTIN; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

MUS;

EID: 34547138949     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.06.164     Document Type: Article

References (32)

1. Wellen K.E., and Hotamisligil G.S. Inflammation, stress and diabetes. J. Clin. Invest. 115 (2005) 1111-1116
2. Hirosumi J., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
3. Tamura Y., Uchida T., Ikeda F., Kumashiro N., Nomiyama T., Sato F., Hirose T., Tanaka Y., Mochizuki H., Kawamori R., and Watada H.. Amelioration of glucose tolerance by hepatic inhibition of nuclear factor κB in db/db mice. Diabetologia 50 (2007) 131-141
4. Bhattacharya S., Dey D., and Roy S.S. Molecular mechanism of insulin resistance. J. Biosci. 32 (2007) 405-413
5. Um S.H., D'Alessio D., and Thomas H. Nutrient overload, insulin resistance and ribosomal protein S6kinase 1, S6K1. Cell Metabol. 3 (2006) 393-402
6. 2-terminal kinase pathwyas in inflammation and origin of obesity and diabetes. Diabetes 54 (2005) S73-S78
7. Aguirre V., Yenush L., Davis R., and White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275 (2000) 9047-9054
8. Bandyopadhyay G.K., Ofrecio J., and Olefsky J.M. Increased p85/55/50 Expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54 (2005) 2351-2359
9. Um S.H., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwex J., and Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
10. Khamzina L., Bergeron S., and Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinol. 146 (2005) 1473-1481
11. Ueno M., Tambascia R.C., Bezerra R.M., Amaral M.E., Carneiro E.M., Folli F., Franchini K.G., and Saad M.J. Regulation of insulin signalling by hyperinsulinaemia:role of IRS-1/2 serine phosphorylation and the mTOR/p70 S6K pathway. Diabetologia 48 (2005) 506-518
12. Krebs M., Brehm A., Artwohl M., Szendroedi J., Nowotny P., Roth E., Furnsinn C., Promintzer M., Anderwald C., Bischof M., and Roden M. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56 (2007) 1600-1607
13. Fong Y.M., Moldawer L.L., Wei H., Calvano S.E., Kenney J.S., Allison A.C., Cerami A., Shires G.T., and Lowry S.F. The acute splanchnic and peripheral tissue metabolic response to endotoxin in human. J. Clin. Invest. 85 (1990) 1896-1904
14. Hoshino K., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., and Akira S. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J. Immunol. 162 (1999) 3749-3752
15. Ling P.R., Mendez B., and Istfan N.W. Effects of systemic infusions of endotoxin, tumour necrosis factor and interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose production and periperhal tissue glucose uptake. Metabolism 43 (1994)
16. Kawai T., and Akira S. TLR signaling. Cell Death Differ. 13 (2006) 816-825
17. Chang L., Karin M., and Mammalian C. MAP kinase signalling cascades. Nature 410 (2001) 37-40
18. Shi H., Inouye K., Tzameli I., Yin H., and Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116 (2006) 3015-3025
19. Tuncman G.L., Solinas G., Chang L., Karin M., and Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 103 (2006) 10741-10746
20. Oguri S., Iwakura Y., and Endo Y. Primary role of Interleukin-1α and Interleukin-1β in lipopolysaccharide-induced hypoglycemia in mice. Clin. Diagn. Lab. Immunol. 9 (2002) 1307-1312
21. Kawai T., Ogawa T., Takeda K., and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1999) 115-122
22. Kawai T., Fujita T., Inoue J., Muhhlradt P.F., Sato S.., Hoshino K.., and Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysacharide-inducible genes. J. Immunol. 167 (2001) 5887-5894
23. Denhardt D.T., Giachelli C.M., and Rittling S.R. Role of osteopontin in cellular signaling and toxicant injury. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 723-749
24. Patarca R., and Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13 (1993) 225-246
25. Giachelli S., and Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 19 (2000) 615-622
26. Takemoto M., Yamazaki M., Ridall A.L., Butler W.T., Matsumoto T., Tamura K., Saito K., and Mori S. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy. Ann. N Y Acad. Sci. 902 (2000) 357-363
27. Ohmori R., Taniguchi H., Takahashi R., Kusuhara M., Nakamura H., and suzu F. Plasma Osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170 (2003) 333-337
28. Yu X.Q., Nikolic-Paterson D.J., Yang N., Mu W., Pichler R., Johnson R.J., Atkins R.C., and Lan H.Y. IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am. J. Pathol. 154 (1999) 833-841
29. Ogawa D., Takata Y., Blaschke F., Chu V.H., Towler D.A., Law R.E., Hsueh W.A., and Bruemmer D. Liver C receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ. Res. 96 (2005) 59-67
30. Lu S., Chen C., Hsu S., and Chen H. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett. 530 (2002) 158-162
31. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu w., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA (2001) 13681-13686
32. Nakamachi T., Gizard F., Heywood E.B., Jones K.L., Zhao Y., Fuentes L., Takebayashi K., Aso Y., Staels B., Inukai T., and Bruemmer D. PPAR{alpha} agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 56 (2007) 1662-1670